Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Different Vicadrostat / Empagliflozin Formulations in Healthy Participants
NCT07845630Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicadrostat and empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from zero to the last quantifiable data point up to 4 days and Maximum measured concentration up to 4 days. Started Oct 2026; status: recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07845630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845630.